GB201205632D0 - Method and apparatus - Google Patents

Method and apparatus

Info

Publication number
GB201205632D0
GB201205632D0 GBGB1205632.1A GB201205632A GB201205632D0 GB 201205632 D0 GB201205632 D0 GB 201205632D0 GB 201205632 A GB201205632 A GB 201205632A GB 201205632 D0 GB201205632 D0 GB 201205632D0
Authority
GB
United Kingdom
Prior art keywords
compositions
active material
pharmaceutical composition
disclosed
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1205632.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectura Ltd
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectura Ltd filed Critical Vectura Ltd
Priority to GBGB1205632.1A priority Critical patent/GB201205632D0/en
Publication of GB201205632D0 publication Critical patent/GB201205632D0/en
Priority to SG10201608088YA priority patent/SG10201608088YA/en
Priority to US14/387,629 priority patent/US20150059746A1/en
Priority to MX2014011795A priority patent/MX2014011795A/es
Priority to NZ629920A priority patent/NZ629920A/en
Priority to EP13715413.4A priority patent/EP2830751A1/en
Priority to SG11201405555RA priority patent/SG11201405555RA/en
Priority to HK15107349.6A priority patent/HK1206670A1/xx
Priority to CN201380016626.5A priority patent/CN104203385A/zh
Priority to AU2013239409A priority patent/AU2013239409A1/en
Priority to KR1020147027247A priority patent/KR20140142264A/ko
Priority to RU2014143807A priority patent/RU2014143807A/ru
Priority to JP2015502460A priority patent/JP2015516950A/ja
Priority to CA2867097A priority patent/CA2867097A1/en
Priority to PCT/GB2013/050847 priority patent/WO2013144655A1/en
Priority to IL234659A priority patent/IL234659A0/en
Priority to IN8753DEN2014 priority patent/IN2014DN08753A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F31/00—Mixers with shaking, oscillating, or vibrating mechanisms
    • B01F31/80—Mixing by means of high-frequency vibrations above one kHz, e.g. ultrasonic vibrations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C19/00—Other disintegrating devices or methods
    • B02C19/06—Jet mills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00—Methods of manufacture, assembly or production
    • A61M2207/10—Device therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
    • B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB1205632.1A 2012-03-30 2012-03-30 Method and apparatus Ceased GB201205632D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB1205632.1A GB201205632D0 (en) 2012-03-30 2012-03-30 Method and apparatus
PCT/GB2013/050847 WO2013144655A1 (en) 2012-03-30 2013-03-28 Method and apparatus
CN201380016626.5A CN104203385A (zh) 2012-03-30 2013-03-28 方法和设备
KR1020147027247A KR20140142264A (ko) 2012-03-30 2013-03-28 방법 및 장치
MX2014011795A MX2014011795A (es) 2012-03-30 2013-03-28 Sistema y método para suministrar el fluido del tratamiento.
NZ629920A NZ629920A (en) 2012-03-30 2013-03-28 A method for making an inhalable pharmaceutical composition using a resonant acoustic blender
EP13715413.4A EP2830751A1 (en) 2012-03-30 2013-03-28 Method and apparatus
SG11201405555RA SG11201405555RA (en) 2012-03-30 2013-03-28 Method and apparatus
HK15107349.6A HK1206670A1 (en) 2012-03-30 2013-03-28 Method and apparatus
SG10201608088YA SG10201608088YA (en) 2012-03-30 2013-03-28 Method and apparatus
AU2013239409A AU2013239409A1 (en) 2012-03-30 2013-03-28 Method and apparatus
US14/387,629 US20150059746A1 (en) 2012-03-30 2013-03-28 Method and apparatus
RU2014143807A RU2014143807A (ru) 2012-03-30 2013-03-28 Способ и прибор
JP2015502460A JP2015516950A (ja) 2012-03-30 2013-03-28 方法と装置
CA2867097A CA2867097A1 (en) 2012-03-30 2013-03-28 Method and apparatus
IL234659A IL234659A0 (en) 2012-03-30 2014-09-15 method and system
IN8753DEN2014 IN2014DN08753A (enExample) 2012-03-30 2014-10-17

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1205632.1A GB201205632D0 (en) 2012-03-30 2012-03-30 Method and apparatus

Publications (1)

Publication Number Publication Date
GB201205632D0 true GB201205632D0 (en) 2012-05-16

Family

ID=46159980

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1205632.1A Ceased GB201205632D0 (en) 2012-03-30 2012-03-30 Method and apparatus

Country Status (16)

Country Link
US (1) US20150059746A1 (enExample)
EP (1) EP2830751A1 (enExample)
JP (1) JP2015516950A (enExample)
KR (1) KR20140142264A (enExample)
CN (1) CN104203385A (enExample)
AU (1) AU2013239409A1 (enExample)
CA (1) CA2867097A1 (enExample)
GB (1) GB201205632D0 (enExample)
HK (1) HK1206670A1 (enExample)
IL (1) IL234659A0 (enExample)
IN (1) IN2014DN08753A (enExample)
MX (1) MX2014011795A (enExample)
NZ (1) NZ629920A (enExample)
RU (1) RU2014143807A (enExample)
SG (2) SG11201405555RA (enExample)
WO (1) WO2013144655A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107851B2 (en) 2012-10-15 2015-08-18 New Jersey Institute Of Technology Solventless mixing process for coating pharmaceutical ingredients
JP2015537025A (ja) * 2012-11-16 2015-12-24 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 音響混合技術を使用して集塊物を作製するためのプロセス
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
US20160235667A1 (en) * 2013-10-02 2016-08-18 Vectura Limited Method and apparatus for making compositions for pulmonary administration
GB201321712D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
US20160317391A1 (en) * 2013-12-17 2016-11-03 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants
ES2701525T3 (es) 2014-07-09 2019-02-22 Arven Ilac Sanayi Ve Ticaret As Un procedimiento para la preparación de formulaciones para inhalación
SG11201700536XA (en) 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
EA201792159A1 (ru) 2015-04-01 2018-01-31 Люпин Атлантис Холдингс Са Способ получения сухих порошкообразных смесей
US9968223B2 (en) 2015-06-12 2018-05-15 Sunbeam Products, Inc. Blending appliance with paddle blade
HK1247150A1 (zh) * 2015-07-07 2018-09-21 Abbvie Inc. 用声学混合自动造粒
JPWO2017047650A1 (ja) * 2015-09-14 2018-06-28 大和製罐株式会社 粉末吸入剤、吸入器、及び粉末吸入剤の製造方法
EP3684338A4 (en) 2017-09-22 2021-06-23 Otitopic Inc. DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
US11642333B2 (en) * 2019-05-23 2023-05-09 Anovent Pharmaceutical (U.S.), Llc Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide
CN111297837B (zh) * 2020-03-26 2022-02-22 上海方予健康医药科技有限公司 一种干粉吸入剂的制备方法
CN113144997B (zh) * 2021-03-23 2022-10-25 西安近代化学研究所 共振声混合中临界波动率确定、混合均匀性判定方法及系统
KR102796431B1 (ko) * 2021-09-17 2025-04-16 주식회사 케이티앤지 흡연 물품 및 에어로졸 발생 시스템
US12157098B2 (en) * 2021-12-14 2024-12-03 Honeywell Federal Manufacturing & Technologies, Llc Resonant acoustic mixing system and method
US20250235399A1 (en) * 2022-04-07 2025-07-24 Board Of Regents, The University Of Texas System Methods of preparing carrier-based dry powders for inhalation
EP4531809A2 (en) * 2022-05-28 2025-04-09 Avalyn Pharma Inc. Nintedanib and nintedanib combination dry powder compositions and uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
JP2004533917A (ja) * 2001-05-01 2004-11-11 グラクソ　グループ　リミテッド 解塊装置および方法
GB0205327D0 (en) * 2002-03-06 2002-04-17 Glaxo Group Ltd compounds
US8501232B2 (en) * 2002-04-23 2013-08-06 Nanotherapeutics, Inc. Process of forming and modifying particles and compositions produced thereby
US7188993B1 (en) * 2003-01-27 2007-03-13 Harold W Howe Apparatus and method for resonant-vibratory mixing
US20060152998A1 (en) * 2003-09-10 2006-07-13 Burr Ronald F Acoustic fluidized bed
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0605676D0 (en) * 2006-03-22 2006-05-03 Vectura Ltd Improvements in extraction of powder formulations
EP2082767A1 (en) * 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
WO2009158300A1 (en) * 2008-06-26 2009-12-30 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
CN102149437B (zh) * 2008-07-18 2017-02-15 普罗索尼克斯有限公司 用于提高氟替卡松颗粒结晶度的方法
HUE038555T2 (hu) * 2010-04-21 2018-10-29 Chiesi Farm Spa Eljárás csökkentett elektrosztatikus töltéssel rendelkezõ részecskék elõállítására
WO2011136363A1 (ja) 2010-04-28 2011-11-03 三洋電機株式会社 回路装置の製造方法
US9763965B2 (en) * 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
JP2015537025A (ja) * 2012-11-16 2015-12-24 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 音響混合技術を使用して集塊物を作製するためのプロセス

Also Published As

Publication number Publication date
IL234659A0 (en) 2014-11-30
HK1206670A1 (en) 2016-01-15
KR20140142264A (ko) 2014-12-11
EP2830751A1 (en) 2015-02-04
WO2013144655A1 (en) 2013-10-03
MX2014011795A (es) 2015-01-12
RU2014143807A (ru) 2016-05-27
JP2015516950A (ja) 2015-06-18
SG10201608088YA (en) 2016-11-29
IN2014DN08753A (enExample) 2015-05-22
NZ629920A (en) 2017-03-31
CN104203385A (zh) 2014-12-10
AU2013239409A1 (en) 2014-09-25
SG11201405555RA (en) 2014-11-27
CA2867097A1 (en) 2013-10-03
US20150059746A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
HK1206670A1 (en) Method and apparatus
CY1121373T1 (el) Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
WO2013021199A3 (en) Eutectic mixture for pulmonary administration
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
TR201000680A2 (tr) Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
CA2897464C (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
EA201400591A1 (ru) Ингалятор
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
PH12016500043A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2012174158A3 (en) Administration of benzodiazepine
LT2701681T (lt) Farmacinės kompozicijos, apimančios vietinį anestetiką, tokį kaip bupivakainas, skirts vietiniam įvedimui į burną arba į gerklę
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
MX2015003765A (es) Arterivirus.
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
WO2011152804A3 (en) Process for dry powder formulations
WO2015049519A3 (en) Method and apparatus for making compositions for pulmonary administration
EP2682098A3 (en) Inhalation Compositions
EP2682100A3 (en) Inhalation Compositions Comprising Muscarinic Receptor Antagonist
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
EA029678B9 (ru) Четвертичные соли пиперидиния

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)